| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $12.6M | -55.7% |
| SG&A Expense | $14.0M | +3.1% |
| Operating Income | -$26.6M | +36.8% |
| Income Tax | $0 | — |
| Net Income | -$26.3M | +37.2% |
| EPS (Basic) | -$6.33 | -322.0% |
| EPS (Diluted) | -$6.33 | -322.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.7M | -74.5% |
| Current Assets | $8.3M | -73.7% |
| Total Assets | $16.9M | -59.2% |
| Current Liabilities | $3.3M | -76.7% |
| Total Liabilities | $10.3M | -54.1% |
| Stockholders' Equity | $6.7M | -65.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$26.8M | +18.8% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | $4.3M | -82.6% |
| Free Cash Flow | -$26.8M | +19.8% |